Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) had its price objective dropped by analysts at Truist Financial from $34.00 to $33.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Truist Financial’s price objective indicates a potential upside of 48.92% from the stock’s current […]

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) issued its quarterly earnings data on Monday. The company reported $4.73 EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $5.33, Zacks reports. Nurix Therapeutics had a negative return on equity of 76.09% and a negative net margin of 928.44%. Nurix Therapeutics Stock Down 0.9% NASDAQ:NRIX […]